☆ 4.6 Meeting Abstract

Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies

JOURNAL OF CROHNS & COLITIS (2021)

Get Full Text
Add to Collection

Journal

JOURNAL OF CROHNS & COLITIS
Volume 15, Issue -, Pages S026-S027

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjab075.025

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.